N/A N=21 Measuring Brain Activity of School Age Children
Perinatal Hypoxia · Dopamine · Neurobehavioral Manifestations
Primary: Structural Integrity of Dopaminergic Circuits — 148.90; 175.93; 177.25; 192.78 mm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=743 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16 — 61.7; 48.9 percentage of participants — p=<0.001
Phase 4 N=1 A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
Epidermal Nevus Syndrome
Primary: The Participant Will Achieve Normal Age-adjusted Phosphorous Levels as Tested by Fasting Serum Lab Values — 0.8; 1.2; 1.3; 1.1 mg/dl
Phase 4 N=34 Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
Caloric Restriction · Exercise · Sleep
Primary: Load Carriage Time — 45.21; 41.58; 50.95; 47.15 min
N/A N=3 Assist-Knee: Energy-Harvesting Knee Prosthesis
Transfemoral Amputation · Artificial Limbs
Primary: Time to Complete Sit-to-Stand — 1.6; 2.2; 1.4 seconds
Phase 2 N=100 Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
COVID-19
Primary: All-Cause Mortality Rate Through Day 29 — 28.0; 32.0 Percentage of participants — p=0.8275
N/A N=228 New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME
Obesity, Childhood · Physical Activity · Food Intake
Primary: Change in Child Body Mass Index (BMI) Z-score — 0.69; 1.03 z-score — p=0.342
Phase 2 N=327 Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
Atopic Dermatitis
Primary: Change From Baseline in Numeric Rating Scale (NRS) for Pruritus in Treated Population Compared to Vehicle Population at Week 8 — -3.8; -2.9; -2.9 score on a scale…
Phase 2 N=4 Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
Alcohol Disorders
Primary: Percent Abstinent Days — 3.13; 100 Percentage of days
N/A N=88 Adolescent Interventions to Manage Self-regulation of T1D (AIMS T1D)
Self-regulation · Medication Adherence
Primary: Change From Baseline in Youth Executive Function (Behavioral EF) at 8 Weeks (Z-score) — 0.02; -0.02 z-score
Phase 3 N=220 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Time to Disease Flare — NA; 27.14 Weeks — p=<0.001
Phase 2 N=117 A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs) — 7; 0; 7; 5 Participants
N/A N=16 Usability Testing for the Reward-based Technology to Improve OUD Treatment
Opioid-use Disorder · Contingency Management · Medication for Opioid-use Disorder
Primary: OARSCM Usability - Phase 1 Usability — 12 Participants
N/A N=49 USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D
Type 1 Diabetes Mellitus
Primary: Change in Hypoglycemia During Closed Loop Control (Assessed by Low Blood Glucose Index [LBGI]) — 2.51; 2.1; 1.28; 1.79 low blood glucose index — p=<0.001
Phase 2 N=202 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants